Despite extensive research and improvements in understanding colorectal cancer (CRC), its
metastatic form continues to pose a substantial challenge, primarily owing to limited …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Background The consensus molecular subtypes (CMSs) of colorectal cancer (CRC) capture
tumor heterogeneity at the gene-expression level. Currently, a restricted number of …

Background Colorectal cancer (CRC) consensus molecular subtypes (CMS) have different
immunological, stromal cell, and clinicopathological characteristics. Single-cell …

Microsatellite-stable colorectal cancer (MSS-CRC) is highly refractory to immunotherapy.
Understanding tumor-intrinsic determinants of immunotherapy resistance is critical to …

Colon cancer inter-tumour heterogeneity is installed on multiple levels, ranging from (epi)
genetic driver events to signalling pathway rewiring reflected by differential gene expression …

The revolution of precision medicine has produced unprecedented seismic shifts in the
treatment paradigm of advanced cancers. Among the major killers, colorectal cancer (CRC) …

Over the past decade, our understanding of the diversity of colorectal cancer has expanded
significantly, raising hopes of tailoring treatments more precisely for individual patients. A …

Purpose: The consensus molecular subtypes (CMS) represent a significant advance in the
understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is …

Gene expression-based subtypes of colorectal cancer have clinical relevance, but the
representativeness of primary tumors and the consensus molecular subtypes (CMS) for …